Methods and compositions for delivering active agents with enhanced pharmacological properties

Abstract

Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

Description

PRIORITY[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 13 / 674,285, filed Nov. 12, 2012, which is a continuation of Ser. No. 12 / 158,190, filed Sep. 2, 2008 (now U.S. Pat. No. 8,334,257), which is a national phase application of PCT Application No. PCT / US2006 / 048572, filed Dec. 20, 2006, and published in English on Jun. 28, 2007, as International Publication No. WO 2007 / 073486, and which claims the benefit of U.S. Provisional Patent Application Ser. No. 60 / 751,896, filed Dec. 20, 2005, the disclosure of each of which is incorporated by reference herein in its entirety.GOVERNMENT FUNDING[0002]This invention was made with Government support under grant number EB00188 and GM-061232 from the National Institutes of Health. The US Government has certain rights to this invention.DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY[0003]The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety:...

AI Technical Summary

Benefits of technology

The present invention provides a method of enhancing the effectiveness of an active agent in a subject by administering it in conjunction with a bioelastic polymer or elastin-like peptide. This can improve the solubility, bioavailability, therapeutic dose, formulation compatibility, resistance to proteolysis, half-life of the active agent, persistence in the body, and rate of clearance from the body of the active agent in the subject. This approach can also reduce systemic toxicity and improve the efficacy of the active agent in treating a particular condition in the subject.

Problems solved by technology

A significant problem with many candidate drugs, or even drugs in clinical use, is insufficient or unsatisfactory in vivo efficacy.

Insufficient in vivo efficacy can be manifested in a variety of ways, such as (i) low bioavailability of the active compound; (ii) undesirably short half-life of the active compound, (iii) and / or undesirably high systemic toxicity of the active compound.

Images